# Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors

> **NCT07170293** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Second Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Solid Cancers

## Interventions

- **DRUG:** Tunlametinib

## Key facts

- **NCT ID:** NCT07170293
- **Lead sponsor:** Tianjin Medical University Second Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2027-08-31
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07170293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07170293, "Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07170293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*